These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16258427)

  • 21. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rapamycin and CCI-779].
    Alexandre J; Raymond E; Armand JP
    Bull Cancer; 1999 Oct; 86(10):808-11. PubMed ID: 10572230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
    Jozwiak J; Jozwiak S; Oldak M
    Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A; Schlitt HJ; Geissler EK
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus: its role in nephrology.
    Lee VW; Chapman JR
    Nephrology (Carlton); 2005 Dec; 10(6):606-14. PubMed ID: 16354246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T; Karashima H
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin as a target in hematological malignancies.
    Abdel-Karim IA; Giles FJ
    Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
    [No Abstract]   [Full Text] [Related]  

  • 34. [Rapamycine and mTOR inhibitors: from bench to bedside].
    Pallet N; Beaune P; Legendre C; Anglicheau D
    Ann Biol Clin (Paris); 2006; 64(2):107-15. PubMed ID: 16556521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pleiotropic effects of mTor inhibitors.
    Ponticelli C
    J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
    Khokhar NZ; Altman JK; Platanias LC
    Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
    Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
    Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.